Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DAVITA INC.DVA · Entity 3482 | Director · Chief Executive Officer | June 15, 2026 | June 17, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | April 30, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DAVITA INC.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 840,408 |
Ending reported balance
After 2026-06-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-15 · Sale · Disposed 30,000 · Balance 879,815 F1: Represents the weighted average sale price of $209.503. The range of prices for the sale of these shares was $209.000 - $210.140 rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2026-06-16 · Sale · Disposed 39,407 · Balance 840,408 F2: Represents the weighted average sale price of $209.278. The range of prices for the sale of these shares was $209.200 - $209.800 rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average sale price of $209.503. The range of prices for the sale of these shares was $209.000 - $210.140 rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2: Represents the weighted average sale price of $209.278. The range of prices for the sale of these shares was $209.200 - $209.800 rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
GILEAD SCIENCES, INC.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,364 |
Reported balance
After 2026-04-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-30 · Grant · Acquired 1,146 · Balance 13,364 F1: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $130.84 · Expires 2036-04-30 | Direct | 4,884 |
Reported balance
After 2026-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-30 · Grant · Acquired 4,884 · Balance 4,884 F2: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.
F2: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2023 Filed May 4, 2023 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014551 · form4.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,392 F1 · security: Represents 1,887 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 3, 2023. Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 22:47 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionStock Appreciation Rights · Derivative | 79,909 | $0.00 Strike: $65.48 | $0.00 |
DisclosureSEC source: 0000927066-22-000117 · wf-form4_165464201687492.xml · derivative · entry 4 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 79,909 shares Expires 2022-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Stock Appreciation Rights were granted on June 6, 2017, which vested 50% each on May 15, 2020 and May 15, 2021. F4 · derivative.expiration_date: Expiration date previously reported in error as May 15, 2022 on Form 4 filed on June 8, 2017. Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 22:47 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 11,326 | $96.70 | $1,095,224.20 |
DisclosureSEC source: 0000927066-22-000117 · wf-form4_165464201687492.xml · nonDerivative · entry 3 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,622 F2 · shares: Represents the shares withheld to satisfy the tax withholding obligation in connection with the exercise of Stock Appreciation Rights reported on this Form 4. Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 22:47 UTC | DAVITA INC. DVA · Entity 3482 | Disposition to issuerCommon Stock | 54,111 | $96.70 | $5,232,533.70 |
DisclosureSEC source: 0000927066-22-000117 · wf-form4_165464201687492.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,948 F1 · shares: Represents the shares withheld in payment of the base price in connection with the exercise of Stock Appreciation Rights reported on this Form 4. Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 22:47 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionCommon Stock | 79,909 | $65.48 | $5,232,441.32 |
DisclosureSEC source: 0000927066-22-000117 · wf-form4_165464201687492.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2022 Filed May 17, 2022 01:46 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 15,298 | $100.05 | $1,530,564.90 |
DisclosureSEC source: 0000927066-22-000083 · wf-form4_165275198824921.xml · nonDerivative · entry 6 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,150 F6 · shares: Shares withheld from issuance to satisfy tax withholding obligation in connection with the vesting of 34,847 shares, which represents 50% of the restricted stock units granted to the Reporting Person on May 15, 2019. Read SEC document |
| May 15, 2022 Filed May 17, 2022 01:46 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 3,873 | $100.05 | $387,493.65 |
DisclosureSEC source: 0000927066-22-000083 · wf-form4_165275198824921.xml · nonDerivative · entry 5 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,448 F5 · shares: Shares withheld from issuance to satisfy tax withholding obligation in connection with the vesting of 8,822 shares, which represents 50% of the restricted stock units granted to the Reporting Person on May 15, 2018. Read SEC document |
| May 15, 2022 Filed May 17, 2022 01:46 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 29,076 | $100.05 | $2,909,053.80 |
DisclosureSEC source: 0000927066-22-000083 · wf-form4_165275198824921.xml · nonDerivative · entry 4 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,321 F4 · shares: Shares withheld from issuance to satisfy tax withholding obligations in connection with the vesting of 66,230 shares, which represents 50% of the shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on May 15, 2019. Read SEC document |
| May 15, 2022 Filed May 17, 2022 01:46 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 12,681 | $100.05 | $1,268,734.05 |
DisclosureSEC source: 0000927066-22-000083 · wf-form4_165275198824921.xml · nonDerivative · entry 3 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,397 F3 · shares: Shares withheld from issuance to satisfy tax withholding obligations in connection with the vesting of 28,884 shares, which represents 50% of the shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on May 15, 2018. Read SEC document |
| May 15, 2022 Filed May 17, 2022 01:46 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 17,233 | $100.05 | $1,724,161.65 |
DisclosureSEC source: 0000927066-22-000083 · wf-form4_165275198824921.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,078 F2 · shares: Shares withheld from issuance to satisfy tax withholding obligations in connection with the vesting of 39,254 shares, which represents 100% of the shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on May 15, 2019. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:46 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 24,890 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-22-000083 · wf-form4_165275198824921.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,311 F1 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units approved by the Issuer's Board of Directors on May 15, 2019 and granted to the Reporting Person, of which 100% vested on May 15, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,851 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001127602-22-013722 · form4.xml · derivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013722 · form4.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,505 F1 · security: Represents 2,444 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013117 · form4.xml · derivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 3, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 3, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013117 · form4.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| April 22, 2022 Filed Apr 27, 2022 00:16 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 14,364 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-22-000066 · wf-form4_165101855641576.xml · nonDerivative · entry 3 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,421 F3 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units approved by the Issuer's Board of Directors on May 15, 2019 and granted to the Reporting Person, of which 100% will vest on May 15, 2022. Read SEC document |
| April 22, 2022 Filed Apr 27, 2022 00:16 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 66,230 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-22-000066 · wf-form4_165101855641576.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,057 F2 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on May 15, 2019, of which 100% will vest on May 15, 2022. Read SEC document |
| April 22, 2022 Filed Apr 27, 2022 00:16 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 28,884 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-22-000066 · wf-form4_165101855641576.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,827 F1 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on May 15, 2018, of which 100% will vest on May 15, 2022. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 18:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-020005 · form4.xml · derivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,223 Underlying: Common Stock · 1,838 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on June 15, 2021. F2 · derivative.expiration_date: 100% of the restricted stock units vested on June 15, 2021. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 18:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-020005 · form4.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 15, 2021 Filed May 19, 2021 00:56 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 11,618 | $125.41 | $1,457,013.38 |
DisclosureSEC source: 0000927066-21-000109 · wf-form4_162138579957519.xml · nonDerivative · entry 5 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,943 F5 · shares: Shares withheld from issuance to satisfy tax withholding obligations in connection with the vesting of 26,464 shares, which represents 50% of the shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on May 15, 2018. Read SEC document |
| May 15, 2021 Filed May 19, 2021 00:56 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 1,994 | $125.41 | $250,067.54 |
DisclosureSEC source: 0000927066-21-000109 · wf-form4_162138579957519.xml · nonDerivative · entry 4 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,561 F4 · shares: Shares withheld from issuance to satisfy tax withholding obligations in connection with the vesting of 4,542 shares, which represents 50% of the shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on May 15, 2018. Read SEC document |
| May 15, 2021 Filed May 19, 2021 00:56 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 3,873 | $125.41 | $485,712.93 |
DisclosureSEC source: 0000927066-21-000109 · wf-form4_162138579957519.xml · nonDerivative · entry 3 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,555 F3 · shares: Shares withheld from issuance to satisfy tax withholding obligation in connection with the vesting of 8,821 shares, which represents 50% of the restricted stock units granted to the Reporting Person on May 15, 2018. Read SEC document |
| May 15, 2021 Filed May 19, 2021 00:56 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 10,525 | $125.41 | $1,319,940.25 |
DisclosureSEC source: 0000927066-21-000109 · wf-form4_162138579957519.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,428 F2 · shares: Shares withheld from issuance to satisfy tax withholding obligations in connection with the vesting of 23,974 shares, which represents 100% of the shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on June 6, 2017. Read SEC document |
| May 15, 2021 Filed May 19, 2021 00:56 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 672 | $125.41 | $84,275.52 |
DisclosureSEC source: 0000927066-21-000109 · wf-form4_162138579957519.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,953 F1 · shares: Shares withheld from issuance to satisfy tax withholding obligations in connection with the vesting of 1,529 shares, which represents 50% of the shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on June 6, 2017. Read SEC document |
| May 12, 2021 Filed May 14, 2021 19:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016783 · form4.xml · derivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 19:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-016783 · form4.xml · derivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 05, 2021 Filed May 6, 2021 00:09 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionStock Appreciation Rights · Derivative | 124,091 | $0.00 Strike: $75.42 | $0.00 |
DisclosureSEC source: 0000927066-21-000082 · wf-form4_162025978253156.xml · derivative · entry 5 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,091 shares Expires 2021-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Stock Appreciation Rights were granted on May 13, 2016, which vested 50% each on May 13, 2019 and May 13, 2020. Read SEC document |
| May 05, 2021 Filed May 6, 2021 00:09 UTC | DAVITA INC. DVA · Entity 3482 | SaleCommon Stock | 27,053 | $122.22 | $3,306,547.51 |
DisclosureSEC source: 0000927066-21-000082 · wf-form4_162025978253156.xml · nonDerivative · entry 4 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,625 Read SEC document |
| May 05, 2021 Filed May 6, 2021 00:09 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 21,171 | $123.36 | $2,611,654.56 |
DisclosureSEC source: 0000927066-21-000082 · wf-form4_162025978253156.xml · nonDerivative · entry 3 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,678 F2 · shares: Represents the shares withheld to satisfy the tax withholding obligation in connection with the exercise of Stock Appreciation Rights reported on this Form 4. Read SEC document |
| May 05, 2021 Filed May 6, 2021 00:09 UTC | DAVITA INC. DVA · Entity 3482 | Disposition to issuerCommon Stock | 75,867 | $123.36 | $9,358,953.12 |
DisclosureSEC source: 0000927066-21-000082 · wf-form4_162025978253156.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,849 F1 · shares: Represents the shares withheld in payment of the base price in connection with the exercise of Stock Appreciation Rights reported on this Form 4. Read SEC document |
| May 05, 2021 Filed May 6, 2021 00:09 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionCommon Stock | 124,091 | $75.42 | $9,358,943.22 |
DisclosureSEC source: 0000927066-21-000082 · wf-form4_162025978253156.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2021 Filed Apr 21, 2021 23:16 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 4,542 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-21-000064 · wf-form4_161904699724458.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,625 F2 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on May 15, 2018, of which 100% will vest on May 15, 2021. Read SEC document |
| April 20, 2021 Filed Apr 21, 2021 23:16 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 1,529 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-21-000064 · wf-form4_161904699724458.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,083 F1 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on June 6, 2017, of which 100% will vest on May 15, 2021. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:00 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 26,464 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-21-000028 · wf-form4_161464323403118.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,554 F2 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on May 15, 2018, of which 100% will vest on May 15, 2021. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:00 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 23,974 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-21-000028 · wf-form4_161464323403118.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,090 F1 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on June 6, 2017, of which 100% will vest on May 15, 2021. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 17:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 189 | $75.50 | $14,269.50 |
DisclosureSEC source: 0001127602-20-020353 · form4.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 22:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 1,838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-019796 · form4.xml · derivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,838 Underlying: Common Stock · 1,838 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on June 15, 2021. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on June 15, 2021. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 22:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 8,667 | $0.00 Strike: $73.97 | $0.00 |
DisclosureSEC source: 0001127602-20-019796 · form4.xml · derivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,667 Underlying: Common Stock · 8,667 shares Expires 2030-06-15 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary measured from June 15, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable on June 15, 2021. Read SEC document |
| May 15, 2020 Filed May 20, 2020 01:18 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 516 | $79.25 | $40,893.00 |
DisclosureSEC source: 0000927066-20-000103 · wf-form4_158993747044288.xml · nonDerivative · entry 3 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,116 F3 · shares: Shares withheld from issuance to satisfy tax withholding obligation in connection with the vesting of 1,172 shares as described in footnote 2 above. Read SEC document |
| May 15, 2020 Filed May 20, 2020 01:18 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 1,172 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-20-000103 · wf-form4_158993747044288.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,632 F2 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on June 6, 2017. Read SEC document |
| May 15, 2020 Filed May 20, 2020 01:18 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 1,267 | $79.25 | $100,409.75 |
DisclosureSEC source: 0000927066-20-000103 · wf-form4_158993747044288.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,460 F1 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on December 24, 2016, in which 2,881 shares vested on May 15, 2020. Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 22:00 UTC | DAVITA INC. DVA · Entity 3482 | GrantStock Appreciation Rights · Derivative | 2,500,000 | $0.00 Strike: $67.80 | $0.00 |
DisclosureSEC source: 0000927066-20-000007 · wf-form4_157990319957516.xml · derivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Common Stock · 2,500,000 shares Expires 2024-11-04 F1 · date: This award was approved by the Compensation Committee of DaVita's Board of Directors on November 4, 2019, subject to stockholder approval to amend its 2011 Incentive Award Plan ("Plan Amendment"). DaVita's stockholder's approved the Plan Amendment on January 23, 2020. F2 · derivative.exercise_date: 50% will vest on each of November 4, 2022, and November 4, 2023, subject to continued service through each applicable vesting date. Read SEC document |
| June 02, 2019 Filed Jun 4, 2019 23:46 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 506 | $43.42 | $21,970.52 |
DisclosureSEC source: 0000927066-19-000104 · wf-form4_155969199960314.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,727 F2 · shares: Shares withheld from issuance to satisfy tax withholding obligation in connection with the vesting for 1,150 shares as described in footnote 1. Read SEC document |
| June 02, 2019 Filed Jun 4, 2019 23:46 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-19-000104 · wf-form4_155969199960314.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,233 F1 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on June 2, 2015, in which 2,405 shares vested on June 2, 2018, and 1,150 shares vested on June 2, 2019. Read SEC document |
| May 15, 2019 Filed May 17, 2019 23:32 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 1,267 | $50.22 | $63,628.74 |
DisclosureSEC source: 0000927066-19-000089 · wf-form4_155813594328484.xml · nonDerivative · entry 3 Rodriguez Javier · CIK 0001415548 · Chief Executive Officer, DKC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,083 F4 · shares: Shares withheld from issuance to satisfy tax withholding obligation in connection with the vesting of 2,880 shares as described in footnote 3 above. Read SEC document |
| May 15, 2019 Filed May 17, 2019 23:32 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 5,761 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-19-000089 · wf-form4_155813594328484.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001415548 · Chief Executive Officer, DKC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,350 F3 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on 12/24/2016, in which 2,880 shares vested on May 15, 2019 and the remaining 2,881 vest on May 15, 2020. Read SEC document |
| May 15, 2019 Filed May 17, 2019 23:32 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 69,694 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-19-000089 · wf-form4_155813594328484.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Chief Executive Officer, DKC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,589 F1 · shares: These restricted stock units are scheduled to vest 50% each on 5/15/2022 and 5/15/2023, subject to continued service through each applicable vesting date. F2 · balance_after: Includes 17,643 restricted stock units, which may be settled solely in shares of common stock, that the Reporting Person had previously reported on Table II. Read SEC document |
| June 02, 2018 Filed Jun 6, 2018 00:17 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 2,405 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-18-000122 · wf-form4_152824421699896.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Chief Executive Officer, DKC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,252 Read SEC document |
| May 15, 2018 Filed May 18, 2018 01:04 UTC | DAVITA INC. DVA · Entity 3482 | GrantRestricted Stock Units · Derivative | 17,643 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000927066-18-000107 · wf-form4_152660547369622.xml · derivative · entry 3 Rodriguez Javier · CIK 0001415548 · Chief Executive Officer, DKC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,643 Underlying: Common Stock · 17,643 shares Expires 2023-05-15 F1 · security: 50% will vest on each of 5/15/2021 and 5/15/2022, subject to continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.